Synlogic, Inc. - SYBX STOCK NEWS

Synlogic, Inc. (Nasdaq: SYBX) has appointed Michael Jensen as Chief Financial Officer, bringing extensive experience in the pharmaceutical and medical device sectors. Jensen's diverse background in finance and operations is seen as crucial for advancing Synlogic's clinical programs, particularly the upcoming Phase 3 study for its lead program in phenylketonuria (PKU). Jensen previously served as CFO at Intrinsic Therapeutics and has held roles at notable companies like Novartis and Siemens. Synlogic aims to leverage synthetic biology to address unmet medical needs with its innovative pipeline.

Synlogic, a clinical-stage biotechnology company, announced that its President and CEO, Aoife Brennan, will participate in two upcoming investor conferences. She will engage in a fireside chat and panel at Chardan’s Microbiome Medicines Summit on March 1, 2022, and present at Oppenheimer’s Healthcare Conference on March 17, 2022. The company is advancing its Synthetic Biotics pipeline, including a Phase 3 study for phenylketonuria planned for late 2022, and collaborations with Roche and Ginkgo Bioworks focused on inflammatory bowel disease and additional preclinical assets.

On February 8, 2022, Synlogic, a clinical-stage biotechnology company (Nasdaq: SYBX), announced upcoming presentations at key investor conferences. Molly Harper, Chief Business Officer, will present at the BIO CEO & Investor Conference on February 14, 2022, while Aoife Brennan, CEO, will participate in a Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022. The company focuses on developing medicines for metabolic diseases using Synthetic Biotics, with a pivotal Phase 3 study for phenylketonuria (PKU) planned for the second half of 2022.

Synlogic, Inc. (SYBX), a clinical-stage biotech company, announced progress towards significant clinical milestones in 2022. The pivotal Phase 3 program for treating phenylketonuria (PKU) is set to initiate in H2 2022 after achieving clinical proof of concept. Multiple clinical read-outs are anticipated across various programs, including treatments for enteric hyperoxaluria and homocystinuria (HCU). The company is advancing collaborations with Roche and Ginkgo Bioworks for novel drug candidates, aiming to address significant unmet medical needs.

Synlogic, Inc. (Nasdaq: SYBX) announced interim data from its Phase 2 SynPheny-1 trial, showing that the Synthetic Biotic medicine SYNB1618 significantly reduced plasma phenylalanine (Phe) levels in patients with phenylketonuria (PKU). Key results included a 40% reduction in D5-Phe absorption and a 20% decrease in mean fasting plasma Phe. The treatment was well tolerated without serious adverse events. Additionally, Synlogic introduced SYNB1934, showcasing enhanced Phe consumption activity, and expects to advance its PKU program toward a Phase 3 study by mid-2022.

Synlogic, Inc. (SYBX) reported its third-quarter financial results for the period ending September 30, 2021. The company recorded a net loss of $16 million, or $0.29 per share, an increase from the $13.2 million loss in Q3 2020. Revenue reached $0.9 million, attributed to its collaboration with Roche. Synlogic is advancing its Phenylketonuria program with positive findings from the Phase 2 SynPheny-1 study, targeting a Phase 3 launch in 2022. Financially, the company holds $150.1 million in cash, sufficient to fund operations into 2024.

Synlogic, Inc. (SYBX) announced new data on phenylketonuria (PKU) treatments at the 14th International Congress of Inborn Errors of Metabolism in Sydney (Nov 21-24, 2021). A late-breaker oral presentation highlighted a reduction in plasma phenylalanine levels with SYNB1618. Additionally, poster presentations showcased SYNB1934's enhanced Phe lowering and its optimized variant. Preclinical data for SYNB1353, targeting homocystinuria, was also presented. Synlogic focuses on microbial engineering to develop Synthetic Biotic medicines for metabolic disorders.

Synlogic (SYBX) and Ginkgo Bioworks (DNA) announced the nomination of SYNB1353, an investigational Synthetic Biotic medicine for homocystinuria (HCU). This marks the first product from their collaboration and the first developed on Ginkgo's platform to enter IND-enabling studies. Synlogic aims to file an IND application for SYNB1353 with the FDA in 2022. SYNB1353 is designed to lower plasma homocysteine by metabolizing methionine in the GI tract, providing new treatment options for patients with HCU, a disorder with limited existing therapies.

Synlogic, Inc. (SYBX) will release its third-quarter 2021 financial results on November 10, 2021, prior to market opening. A conference call will follow at 8:30 am ET, available via telephone and webcast. Additionally, President and CEO Aoife Brennan will present at the Jefferies London Healthcare Conference on November 18-19. Synlogic focuses on synthetic biology to create therapeutics for metabolic disorders, including Phenylketonuria and Enteric Hyperoxaluria.